Načítá se...
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial res...
Uloženo v:
| Vydáno v: | Drugs R D |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6277321/ https://ncbi.nlm.nih.gov/pubmed/30232719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-018-0247-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|